related documents
- Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial Conference Paper
- Everolimus Added to Exemestane Reduced Bone Markers and Disease Progression in Bone in Postmenopausal Women with Advanced Breast Cancer: Updated Results From the BOLERO-2 Trial Conference Paper
- Everolimus Added to Exemestane Reduced Bone Markers in Postmenopausal Women with Advanced Breast Cancer (ABC): the BOLERO-2 Trial Conference Paper
- Impact of Survivorship Care Plans (SCP) On Adherence to Guidelines, Health Service Measures, and Patient-reported Outcomes (PRO): Extended Results of a Multicenter Randomized Clinical Trial (RCT) with Breast Cancer Survivors Conference Paper